In combination with rhIL-2, exp_GAIA integrates endogenous NK activity with induction of long-lasting, CD8+T cell-dependent antitumor immunity via a CCR5-CCL3-NK-IFN-γ-CD8 pathway, reinforced ICD with CRT exposure. These findings support exp_GAIA+rhIL-2 as a new NK-based strategy for durable control of solid tumors.

2 days ago

Journal

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CCR5 (C-C Motif Chemokine Receptor 5) • CALR (Calreticulin) • CCL3 (C-C Motif Chemokine Ligand 3)

GAIA-102

5ms

GAIA-102-PD: GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites (clinicaltrials.gov)

P1/2, N=130, Recruiting, Kyushu University | N=96 --> 130 | Trial completion date: Jun 2027 --> Mar 2029 | Trial primary completion date: Dec 2026 --> Dec 2028

5 months ago

Enrollment change • Trial completion date • Trial primary completion date

CXCL11 (C-X-C Motif Chemokine Ligand 11)

Keytruda (pembrolizumab) • GAIA-102

2years

Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors (clinicaltrials.gov)

P1, N=56, Recruiting, Kyushu University | N=36 --> 56

2 years ago

Enrollment change

Opdivo (nivolumab) • GAIA-102

almost4years

GAIA-102-PD: GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites (clinicaltrials.gov)

P1/2, N=96, Recruiting, Kyushu University

almost 4 years ago

New P1/2 trial

CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL20 (C-C Motif Chemokine Ligand 20) • CXCL11 (C-X-C Motif Chemokine Ligand 11)

Keytruda (pembrolizumab) • GAIA-102